M
Michelle Lai
Researcher at Beth Israel Deaconess Medical Center
Publications - Â 113
Citations - Â 3682
Michelle Lai is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Medicine. The author has an hindex of 24, co-authored 94 publications receiving 2703 citations. Previous affiliations of Michelle Lai include Curtin University & Monash University.
Papers
More filters
Journal ArticleDOI
A Survey of Liver Transplantation from Living Adult Donors in the United States
Robert S. Brown,Mark W. Russo,Michelle Lai,Mitchell L. Shiffman,Michael C. Richardson,James E. Everhart,Jay H. Hoofnagle +6 more
TL;DR: Adult-to-adult liver transplantation from a living donor is increasingly performed in the United States but is concentrated in a few large-volume centers.
Journal ArticleDOI
The clinical significance of persistently normal ALT in chronic hepatitis B infection.
TL;DR: Subgroup analysis showed the majority with fibrosis belonged to the high normal ALT group and that only a minority who were young and immune tolerant had significant findings on biopsy, and increasing age, higher ALT, higher grade of inflammation on bi autopsy, and HBeAg positivity predicted fibrosis.
Journal ArticleDOI
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba,Zeid Kayali,Mazen Noureddin,Peter Ruane,Eric Lawitz,Michael J. Bennett,L. Wang,Eliza Harting,Jacqueline M. Tarrant,B. Mccolgan,Chuhan Chung,Adrian S. Ray,G. Mani Subramanian,Robert P. Myers,Michael S. Middleton,Michelle Lai,Michael Charlton,Stephen A. Harrison +17 more
TL;DR: 12-week administration of GS-0976 20 mg decreased hepatic steatosis, selected markers of fibrosis, and liver biochemistry, and the relation between dose and efficacy was evaluated.
Journal ArticleDOI
The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase
Phillip J. White,Phillip J. White,Robert W. McGarrah,Robert W. McGarrah,Paul A. Grimsrud,Shih Chia Tso,Wen-Hsuan Yang,Jonathan M. Haldeman,Grenier-Larouche Thomas,Jie An,Amanda L. Lapworth,Inna Astapova,Inna Astapova,Sarah A. Hannou,Tabitha George,Michelle Arlotto,Lyra B. Olson,Michelle Lai,Guo-Fang Zhang,Guo-Fang Zhang,Olga Ilkayeva,Mark A. Herman,Mark A. Herman,R. Max Wynn,David T. Chuang,Christopher B. Newgard,Christopher B. Newgard +26 more
TL;DR: These studies identify BDK and PPM1K as a ChREBP-regulated node that integrates BCAA and lipid metabolism and manipulation of the BDK:P PM1K ratio relieves key metabolic disease phenotypes in a genetic model of severe obesity.
Journal ArticleDOI
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani,M. Abdelmalek,Guadalupe Garcia-Tsao,Raj Vuppalanchi,Naim Alkhouri,Mary E. Rinella,Mazen Noureddin,Maxmillan Pyko,Mitchell L. Shiffman,Arun J. Sanyal,Adam Allgood,Harold Shlevin,Rex Horton,Eliezer Zomer,William Irish,Zachary Goodman,Stephen A. Harrison,Peter G. Traber,Manal F. Abdelmalek,Luis A. Balart,Brian B. Borg,Michael Charlton,Hari S. Conjeevaram,Michael Fuchs,Reem Ghalib,Pierre M. Gholam,Dina Halegoua-De Marzio,S Harrison,Christopher Jue,Nyingi Kemmer,Kris V. Kowdley,Michelle Lai,Eric Lawitz,Rohit Loomba,Angelo H. Paredes,Don C. Rockey,Miguel Rodriguez,Raymond A. Rubin,Michael P. Ryan,Andrew Scanga,Thomas Sepe,Brent Tetri,Paul J. Thuluvath,Dawn M. Torres,John M. Vierling,Julia Wattacheril,Amanda Weiland,Donald Zogg +47 more
TL;DR: In a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly infusion of belapectin was safe but not associated with significant reduction in HVPG or fibrosis, compared with placebo, however, in a subgroup analysis of patients without esophageal varices, 2 mg/kg bela Expectin did reduce HvPG and development of varices.